Thyroid Panel - References

Thyroid Panel — Literature Dossier

Navigation

• Backed Topic Note: Thyroid Panel
• References Hub: 03 - Diagnostics & Quantified Self References MOC
• Parent Silo MOC: 03 - Diagnostics & Quantified Self MOC

---

Landmark Peer-Reviewed Studies

1. Rodondi et al. (2010) — Subclinical Hypothyroidism and Coronary Heart Disease Mortality

• Citation: Rodondi, N., den Elzen, W. P., Bauer, D. C., Cappola, A. R., Razvi, S., Walsh, J. P., … & Thyroid Studies Collaboration. (2010). Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA, 304(12), 1365–1374.
• Identifiers: DOI: 10.1001/jama.2010.1361 (DOI · SciDB · Scholar) | PMID: 20858880 (PubMed · Europe PMC) | PMCID: PMC3923470 (PMC Full Text)
• Study Design & Cohort: Individual participant data meta-analysis of 11 prospective cohorts ($N=55,287$ adults with $542,494$ person-years of follow-up).
• Quantitative Findings & Diagnostic Thresholds:
  • Compared to euthyroid reference ($0.50–4.49\text{ mIU/L}$), CHD mortality escalated progressively with TSH elevation ($p<0.001$ for trend), reaching $\text{HR }1.58$ ($95\%\text{ CI }1.10–2.27$) for CHD mortality and $\text{HR }1.89$ ($95\%\text{ CI }1.28–2.80$) for CHD events at $\text{TSH }\ge 10\text{ mIU/L}$, with early atherogenic lipid shifts starting above $\text{TSH }2.5–3.0\text{ mIU/L}$ in younger adults.

2. Iervasi et al. (2003) — Low Free T3 as Strongest Predictor of Death in Cardiac Patients

• Citation: Iervasi, G., Pingitore, A., Landi, P., Raciti, M., Ripoli, A., Scarlattini, M., … & Donato, L. (2003). Low-T3 syndrome: a strong prognostic predictor of death in patients with heart disease. Circulation, 107(5), 708–713.
• Identifiers: DOI: 10.1161/01.cir.0000048124.64204.3f (DOI · SciDB · Scholar) | PMID: 12578873 (PubMed · Europe PMC)
• Study Design & Cohort: Prospective cohort ($N=573$ consecutive cardiac patients with normal TSH and Free T4 evaluated for peripheral Free T3 status).
• Quantitative Findings & Diagnostic Thresholds:
  • Patients with low Free T3 ($<3.1\text{ pmol/L}$ or $<2.0\text{ pg/mL}$) had a multivariable-adjusted cardiac mortality $\text{HR of }3.57$ ($95\%\text{ CI }1.65–7.76$, $p=0.0004$) and all-cause mortality $\text{HR of }2.95$, proving Free T3 is the highest-leverage prognostic marker of cellular thyroid bioactivity.

3. Wichman et al. (2016) — Selenium Supplementation Reduces Autoimmune TPO Antibodies

• Citation: Wichman, J., Winther, K. H., Bonnema, S. J., & Hegedüs, L. (2016). Selenium Supplementation Significantly Reduces Thyroid Autoantibody Levels in Patients with Chronic Autoimmune Thyroiditis: A Systematic Review and Meta-Analysis. Thyroid, 26(12), 1681–1692.
• Identifiers: DOI: 10.1089/thy.2016.0256 (DOI · SciDB · Scholar) | PMID: 27702392 (PubMed · Europe PMC)
• Study Design & Cohort: Systematic review and meta-analysis of 16 controlled clinical trials ($N=1,494$ patients with Hashimoto’s autoimmune thyroiditis).
• Quantitative Findings & Diagnostic Thresholds:
  • Selenium supplementation ($200\mu \text{g/day}$ selenomethionine) significantly decreased serum TPOAb at 3 months ($\text{WMD }-271\text{ IU/mL}$, $p<0.0001$), 6 months ($\text{WMD }-283\text{ IU/mL}$), and 12 months ($\text{WMD }-423\text{ IU/mL}$), and reduced TgAb at 12 months ($\text{WMD }-193\text{ IU/mL}$).

4. Nordio & Basciani (2017) — Myo-Inositol Plus Selenium Restores Euthyroidism in Subclinical Hypothyroidism

• Citation: Nordio, M., & Basciani, S. (2017). Myo-inositol plus selenium supplementation restores euthyroid state in Hashimoto’s patients with subclinical hypothyroidism. European Review for Medical and Pharmacological Sciences, 21(2 Suppl), 51–59.
• Identifiers: PMID: 28724175 (PubMed · Europe PMC)
• Study Design & Cohort: Prospective clinical trial ($N=168$ patients with Hashimoto’s subclinical hypothyroidism, $\text{TSH }3.0–6.0\text{ mIU/L}$) randomized to $600\text{ mg}$ myo-inositol + $83\mu \text{g}$ L-selenomethionine vs. selenium alone for 6 months.
• Quantitative Findings & Diagnostic Thresholds:
  • Combined Myo-inositol + Selenium reduced TSH from $4.22\pm 0.58\text{ mIU/L}$ to $3.01\pm 0.70\text{ mIU/L}$ ($p<0.001$), increased Free T4 and Free T3 significantly ($p<0.01$), and lowered TPOAb and TgAb titers significantly more than selenium monotherapy.